Breast Cancer: Triple - Negative: Epidemiology and

Dublin, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Breast Cancer: Triple - Negative: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following questions: - Which branded therapies will have the largest commercial potential in the triple-negative breast cancer market? - What impact will immunotherapies have on treatment algorithms in triple-negative breast cancer? - How will competing poly (ADP-ribose)polymerase (PARP) inhibitors Lynparza, niraparib, talazoparib, and veliparib fare against one another? - How will pipeline therapies aim to address areas of unmet need? - When will generic and biosimilar therapies enter the market and what impact will they have on revenues? Key Topics Covered: FORECAST: TRIPLE-NEGATIVE BREAST CANCER - Executive Summary - Market Overview and Trends - Market Definition and Methodology - Abraxane (albumin-bound paclitaxel) - Atezolizumab - Avastin (bevacizumab) - glembatumumab vedotin - Halaven (eribulin mesylate) - Keytruda (pembrolizumab) - Lynparza (olaparib) - Niraparib - sacituzumab govitecan - Talazoparib - Veliparib - Primary Research Methodology TREATMENT: TRIPLE-NEGATIVE BREAST CANCER - Executive Summary - Disease Definition and Diagnosis - Primary Research Methodology - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends - Unmet Needs in Triple-Negative Breast Cancer EPIDEMIOLOGY: TRIPLE-NEGATIVE BREAST CANCER - Executive Summary - Disease Background - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: TRIPLE-NEGATIVE BREAST CANCER - Executive Summary - Product Overview - Product profile: Abraxane - Product profile: Avastin - Product profile: Halaven PIPELINE: TRIPLE-NEGATIVE BREAST CANCER - Executive Summary - Clinical Pipeline Overview - Target Product Profile - Product profile (late stage): Keytruda - Product profile (late stage): Lynparza - Product profile (late stage): atezolizumab - Product profile (late stage): glembatumumab vedotin - Product profile (late stage): niraparib - Product profile (late stage): sacituzumab govitecan - Product profile (late stage): talazoparib - Product profile (late stage): veliparib For more information about this report visit http://www.researchandmarkets.com/research/l9...ast_cancer

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Women's Health, Breast Cancer Drugs